Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid

Osteoporosis International

Volumn 22, Issue 8, 2011, Pages 2337-2345

  Silverman, S L ^a   Kriegman, A ^b   Goncalves, J ^b   Kianifard, F ^b   Carlson, T ^c   Leary, E ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Pacific Biomarkers   (United States)

Author keywords

Cytokines; Fluvastatin; Inflammatory biomarkers; Osteoporosis; Post dose symptoms; Zoledronic acid

Indexed keywords

C REACTIVE PROTEIN; FLUINDOSTATIN; GAMMA INTERFERON; IBUPROFEN; INTERLEUKIN 6; PARACETAMOL; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BODY TEMPERATURE; BONE MASS; CONTROLLED STUDY; CONVULSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OSTEOPOROSIS; PAIN; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYMPTOM; SYNCOPE; UVEITIS;

ACETAMINOPHEN; ACUTE-PHASE REACTION; AGED; ANTIPYRETICS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FATTY ACIDS, MONOUNSATURATED; FEMALE; FEVER; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMIDAZOLES; INDOLES; INFLAMMATION MEDIATORS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TREATMENT OUTCOME;

EID: 79960216013     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1448-2     Document Type: Article

References (14)

1. DM Black PD Delmas R Eastell, et al. 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822 17476007 10.1056/NEJMoa067312 1:CAS:528:DC%2BD2sXltVSktLc%3D (Pubitemid 46698462)
2. KW Lyles CS Colón-Emeric JS Magaziner, et al. 2007 Zoledronic acid and clinical fractures and mortality after hip fracture N Engl J Med 357 1799 1809 17878149 10.1056/NEJMoa074941 1:CAS:528:DC%2BD2sXht1Kit7nN (Pubitemid 350044800)
3. T Tanvetyanon PJ Stiff 2006 Management of the adverse effects associated with intravenous bisphosphonates Ann Oncol 17 897 907 16547070 10.1093/annonc/mdj105 1:STN:280:DC%2BD283nslensA%3D%3D (Pubitemid 43785797)
4. Reclast® (zoledronic acid) prescribing information (2009) Novartis Pharmaceuticals, East Hanover, NJ
5. D Thiébaud A Sauty P Burckhardt, et al. 1997 An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates Calcif Tissue Int 61 386 392 9351880 10.1007/s002239900353 (Pubitemid 27507904)
6. G Dicuonzo B Vincenzi D Santini, et al. 2003 Fever after zoledronic acid administration is due to increase in TNF-α and IL-6 J Interferon Cytokine Res 23 649 654 14651779 10.1089/107999003322558782 1:CAS:528: DC%2BD3sXptVyru74%3D (Pubitemid 37452905)
7. AJ Roelofs M Jauhiainen H Mönkkönen, et al. 2009 Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP Br J Haematol 144 245 250 19016713 10.1111/j.1365-2141.2008.07435.x
8. V Lafont J Liautard M Sable-Teychene, et al. 2001 Isopentenyl pyrophosphate, a mycobacterial non-peptidic antigen, triggers delayed and highly sustained signaling in human gamma delta T lymphocytes without inducing down-modulation of T cell antigen receptor J Biol Chem 276 19 15961 15967 11278429 10.1074/jbc.M008684200 1:CAS:528:DC%2BD3MXjvFaksbg%3D
9. B Cipriani G Borsellino F Poccia, et al. 2000 Activation of C-C beta-chemokines in human peripheral blood gamma delta T cells by isopentenyl pyrophosphate and regulation by cytokines Blood 95 1 39 47 10607682 1:CAS:528:DC%2BD3cXhslKjtg%3D%3D (Pubitemid 30017222)
10. KL Kavanagh K Guo JE Dunford, et al. 2006 The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs Proc Natl Acad Sci USA 103 7829 7834 16684881 10.1073/pnas.0601643103 1:CAS:528: DC%2BD28XlsVGksL0%3D
11. JR Green 2004 Bisphosphonates: preclinical review Oncologist 9 Suppl 4 3 13 15459425 10.1634/theoncologist.9-90004-3 1:CAS:528:DC%2BD2cXpslGhtb0%3D (Pubitemid 39363164)
12. K Thompson MJ Rogers 2004 Statins prevent bisphosphonate-induced γ, δ-T-cell proliferation and activation in vitro J Bone Miner Res 19 278 288 14969398 10.1359/JBMR.0301230 1:CAS:528:DC%2BD2cXhs1elsr0%3D (Pubitemid 38116742)
13. MB Pepys GM Hirschfield 2003 C-reactive protein: a critical update J Clin Invest 111 1805 1812 12813013 1:CAS:528:DC%2BD3sXkvV2ktb0%3D (Pubitemid 38057722)
14. T Srivastava CJ Haney US Alon 2009 Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion J Bone Miner Res 24 334 337 18847329 10.1359/jbmr.081016